Stock 1177 SINO BIOPHARMACEUTICAL LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

All News Sino Biopharmaceutical Limited

Equities

1177

KYG8167W1380

Market Closed - Hong Kong S.E.
Other stock markets
 04:08:35 2024-04-19 am EDT 		5-day change 1st Jan Change
2.34 HKD -3.70% Intraday chart for Sino Biopharmaceutical Limited -16.13% -32.56%
10:20am Sino Biopharmaceutical Reaches Primary Endpoint for Clinical Research of Myelofibrosis Drug MT
Apr. 17 Sino Biopharm EBT Buys Back HK$12 Million Worth of Shares MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Sino Biopharmaceutical Reaches Primary Endpoint for Clinical Research of Myelofibrosis Drug
MT
Sino Biopharm EBT Buys Back HK$12 Million Worth of Shares
MT
Sino Biopharmaceutical Presents Cancer Drug's Phase-II Clinical Trial Results at AACR 2024
MT
Sino Biopharmaceutical Trustee Repurchases Shares
MT
Sino Biopharmaceutical to Develop Boehringer Ingelheim's Cancer Treatments in China
MT
Sino Biopharmaceutical Limited Enters into Strategic Partnership with Boehringer Ingelheim on Innovative Oncology Portfolio in China
CI
Sino Biopharmaceutical's Attributable Profit Drops 8.3% in 2023
MT
Sino Biopharm (1177.HK) Announces 2023 Annual Results
AQ
Sino Biopharmaceutical Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 5 July 2024
CI
Sino Biopharmaceutical Limited Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Sino Biopharmaceutical's Diagnostic Agent Injection Gets Marketing Nod in China
MT
Sino Biopharmaceutical Limited Announces Approval for Marketing of Iopromide Injection
CI
Sino Biopharmaceutical's Developing Two Drugs for MASH
MT
Nomura Adjusts Sino Biopharmaceutical’s Price Target to HK$6.16 From HK$6.63, Keeps at Buy
MT
Sino Biopharmaceutical Limited Provides Update on Development Progress of Mash Products "Lanifibranor" and "TQA2225"
CI
Sino Biopharmaceutical to Present Cancer Drug Phase II Trial Findings at 2024 AACR
MT
Sino Biopharmaceutical Limited Announces Latest Results of Phase II Clinical Study of KRAS G12C Inhibitor Garsorasib Tablet
CI
Hong Kong Shares Slump Amid Chinese Growth Concerns
MT
Sino Biopharmaceutical Limited Announces Acceptance of the New Indication Application for Marketing of Anlotinib Hydrochloride Capsules and Anti Pd-L1 Benmelstobart
CI
Sino Biopharmaceutical's Anti-Cancer Drug Under Priority Review in China
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 1177 Stock
  4. News Sino Biopharmaceutical Limited